Short ratio of Exelixis, Inc.
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
|PLPM Planet Payment, Inc.||NASDAQ > Miscellaneous > Business Services||0.48|
|TRST TrustCo Bank Corp NY||NASDAQ > Finance > Major Banks||0.48|
|SCHL Scholastic Corporation||NASDAQ > Consumer Services > Books||0.48|
|HDNG Hardinge Inc.||NASDAQ > Capital Goods > Industrial Machinery/Components||0.49|
|CLF Cliffs Natural Resources Inc.||NYSE > Basic Industries > Precious Metals||0.49|
|KL Kirkland Lake Gold Ltd.||NYSE > Basic Industries > Precious Metals||0.49|
|EXEL Exelixis, Inc.||NASDAQ > Health Care > Biotechnology: Commercial Physical & Biological Resarch||0.49|
|HCC Warrior Met Coal, Inc.||NYSE > Energy > Coal Mining||102.00|
|WTM White Mountains Insurance Group, Ltd.||NYSE > Finance > Property-Casualty Insurers||128.23|
|NVR NVR, Inc.||NYSE > Capital Goods > Homebuilding||135.95|
|SEB Seaboard Corporation||NYSEMKT > Finance > Investment Bankers/Brokers/Service||279.36|
|DCIX Diana Containerships Inc.||NASDAQ > Transportation > Marine Transportation||648.16|
|BRK-A Berkshire Hathaway Inc.||NYSE > Finance > Property & Casualty Insurance||11,356.35|